A C.D.C. panel recommends J.&J. pictures restart with a label noting the chance of very uncommon blood clots.

Almost 8 million doses of the Johnson & Johnson vaccine have now been given. There was less than one case per million doses in men and women aged 50 and over.

The coagulation disorder is “rare but clinically severe,” said Dr. Tom Shimabukuro, Assistant Director of the CDC Vaccination Safety Office, at the meeting.

About 10 million doses or more of the Johnson & Johnson vaccine, made at the company’s factory in the Netherlands, are on shelves in the United States and could be used immediately.

The vaccine has enormous potential benefits for the population. If vaccinations are resumed for all adults, a model developed by CDC scientist Dr. Sara Oliver can expect 26 to 45 cases of coagulation disorder in the next six months. However, 600 to 1,400 fewer Covid-19-related deaths would be expected over the same period.

The vaccine, which is easy to store and only requires one shot, is also great for hard-to-reach populations, including people who are at home, homeless, or incarcerated.

Other potential cases of the coagulation disorder, including some in men, are currently being investigated. The CDC scientist also mentioned a case that occurred in a 25-year-old man who was taking part in a clinical trial of the vaccine.

Twelve of the 15 women in the confirmed cases developed blood clots in the brain. Many had blood clots elsewhere as well. Initial symptoms, which include a headache, usually begin six or more days after vaccination, said Dr. Shimabukuro. As the disorder develops, it can cause increased headaches, nausea and vomiting, abdominal pain, weakness in one side of the body, difficulty speaking, loss of consciousness, and seizures.

Comments are closed.